OncoMatch/Clinical Trials/NCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Is NCT06297226 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Arlocabtagene Autoleucel for multiple myeloma.
Treatment: Arlocabtagene Autoleucel — The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunomodulatory drug
Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy]
Must have received: proteasome inhibitor
Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy]
Must have received: anti-CD38 therapy
Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy]
Must have received: anti-BCMA therapy
Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy]
Cannot have received: GPRC5D-directed therapy
Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) · Los Angeles, California
- UCSF Helen Diller Medical Center at Parnassus Heights · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify